YOU MATTER.
Upcoming Events
Kidney Cancer Support Group - Charlotte
February 25 @ 07:00 PMKidney/Bladder Cancer Support Group - Seattle
March 02 @ 09:00 PMKidney Cancer Support Group - Charlotte
March 25 @ 07:00 PM
Publications
0
%
5-Year Survival Rate Percentage increase from 2008 through 2014
0
Estimated new cases in the US, this year
0
Estimated Deaths in the US, this year
0
People are living with kidney and renal pelvis cancer, according to NCI SEER data from 2015
Evaluate your treatment options and make decisions
From the Pressroom
News from Kidney Cancer Association This feed has been created by Kidney Cancer Association
-
Dr. McDermott on Single-Agent Pembrolizumab in...
on February 20, 2019 at 7:52 pm
In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non–clear cell renal cell carcinoma (RCC).02/20/2019 […]
-
New therapeutic target found for aggressive...
on February 19, 2019 at 3:23 pm
Researchers at the University of Texas MD Anderson Cancer Center recently discovered a new therapeutic target for malignant rhabdoid tumors (MRT). MRT is a rare pediatric cancer that commonly starts in the kidneys. Dr. Pavlos Msaouel, who was a 2017 Conquer Cancer Foundation Young Investigator […]
-
ASCO GU 2019: First-line Pembrolizumab...
on February 19, 2019 at 3:20 pm
Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first line pembrolizumab monotherapy in non-clear cell advanced RCC.02/19/2019 […]
YOU MATTER.
WE CARE.
YOU ARE NOT ALONE.
Kidney Cancer Association
The Kidney Cancer Association (KCA) is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals globally. It is the world’s first international charity dedicated specifically to the eradication of death and suffering from renal cancers.
Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent pembrolizumab in the treatment of patients with advanced renal cell carcinoma.
onclive.com
ASCO GU 2019: First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell Renal Cell Carcinoma: Results from KEYNOTE-427 Cohort B
ASCO GU 2019 renal cell carcinomas, KEYNOTE 427 Cohort B
urotoday.com
2 days ago
In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non–clear cell renal cell... https://t.co/0FMTnSXjSn
In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non–clear cell renal cell... https://t.co/0FMTnSXjSn
In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non–clear cell renal cell... https://t.co/0FMTnSXjSn
— Kidney Cancer (@KidneyCancer) February 20, 2019
3 days ago
Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first line pembrolizumab monotherapy in non-clear cell advanced RCC. https://t.co/tN4i9RHthI
Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first line pembrolizumab monotherapy in non-clear cell advanced RCC. https://t.co/tN4i9RHthI
Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first line pembrolizumab monotherapy in non-clear cell advanced RCC. https://t.co/tN4i9RHthI
— Kidney Cancer (@KidneyCancer) February 19, 2019
4 days ago
#GU19 @QMBCI research shows combining #immunotherapy drug #pembrolizumab with #targetedtherapy #axitinib helps people with advanced #kidneycancer live longer #kcsm https://t.co/Tbuh9jFDMp
#GU19 @QMBCI research shows combining #immunotherapy drug #pembrolizumab with #targetedtherapy #axitinib helps people with advanced #kidneycancer live longer #kcsm https://t.co/Tbuh9jFDMp
#GU19 @QMBCI research shows combining #immunotherapy drug #pembrolizumab with #targetedtherapy #axitinib helps people with advanced #kidneycancer live longer #kcsm https://t.co/Tbuh9jFDMp
— Kidney Cancer (@KidneyCancer) February 18, 2019